ALK Positive

Thinking about clinical trials? 👀 Join us TONIGHT at 7 PM ET for Clinical Trials Connect — hear perspectives from ALK+ patients, ask questions, and discuss Dr. Ken Culver’s paper on clinical research participation. To learn more and join: alkpositive.org/event/clinical…

This #ClinicalTrialsDay, we are grateful to the patients and families who make progress in #CancerResearch possible. Over the past five years, our clinical trials and research studies have reached hundreds of patients. Together, these efforts are helping researchers better understand how cancers respond, evolve, and recur across #Glioblastoma, #AML, #PancreaticCancer, and #OvarianCancer. Every patient who participates in research helps move the field forward and brings us closer to cures.

Reminder: Join Us Tonight! Don’t miss tonight’s webinar with Dr. Ross Camidge and Nancee Pronsati discussing the evolving landscape of ALK+ lung cancer care, treatment, side effect management, research, and advocacy. Register here: tinyurl.com/8pnek2mz

Upcoming Webinar: Living Well with ALK+ Lung Cancer Join The Patient Story on Tuesday, May 19 for an important conversation featuring Dr. Ross Camidge and ALK Positive Board member Nancee Pronsati. Register now: tinyurl.com/8pnek2mz #ALKPositive #LungCancer #ALK #NSCLC

Tonight at 7 PM ET: Join ALKtALK with Dr. Ken Culver for updates on ALK Positive’s research initiatives, including clinical & preclinical work, support for young investigators, and expanded clinical trial opportunities. alkpositive.org/living-with-al… #ALKPositive #FueltheCure

🫁 Important contribution addressing one of the most challenging scenarios in #thoraciconcology: #lungcancer diagnosed during #pregnancy. 🤰 Key takeaways: • Multidisciplinary care is essential 🧑🏽‍⚕️👩‍⚕️👨🏾‍⚕️ • Comprehensive molecular profiling remains critical 🧬 #ALKpositive #EGFR • More prospective data are urgently needed to guide treatment decisions for both mother and fetus 📈 Congratulations to the team on this important work during #WomensHealthMonth and ongoing @YoungLungCancer awareness efforts. @GO2forLungCancr @LUNGevity @ALKpositiveinc @EGFRResisters @IASLC @OncoAlert @ALKpositiveINT @EgfrUk @ASCO @myESMO @lcrf_org @OncodailyLung @NehemiasGuevar5 @Florez_Lab @Florez_Lab @COlazagasti

Thanks to Leif and the whole crew at The Cork 50131 for hosting us! It was a great time learning about Spanish wines and raising money for @ALKPositiveinc!

Join us on May 14 at 1.30pm ET for a conversation on how heritable genetics can drive the next generation of lung cancer research. Register: LCRF.org/together #lungcancer #research #genetics

As #HopeSummit closes, we’re reflecting on a weekend full of connection & hope 🤍 From Dr @DRCamidge’s keynote to the ALK breakout with Dr. David Gerber, it was powerful to come together—patients, care partners, advocates, clinicians. We leave energised to keep sharing hope 💙

Join us this Sunday, May 3 at 7pm ET: ALKtALK with Timothy Burns, MD, PhD, & Joshua Palmer, MD (OSUCCC – James). ALK-positive lung cancer: brain progression raises urgent questions—stay on TKI, radiate, surgery, or leptomeningeal disease? Live Q&A Join: alkpositive.org/living-with-al…

🎉 A highlight from #AACR26 — our Executive & Medical Director, Dr. Ken Culver, had the honor of meeting Dr. Alice Tzeng, the inaugural recipient of the AACR-ALK Positive Lung Cancer Research Fellowship! #ALKPositive #LungCancer #CancerResearch #AACR26 #PatientAdvocacy

Findings from surgery after systemic tx in NSCLC with pleural mets: 📊 Imaging predicted pleural response, offering needed criteria in a space where clear benchmarks have been lacking 📈 Most pts (70.8%) had no residual pleural disease at surgery 🔗 jtcvsopen.org/article/S2666-…

The replay from our latest ALKtALK is live! 🎬 Dr. Alexander Spira joined us to discuss two clinical trials for ALK+ patients, TRI-611 and Gilteritinib, and what they could mean for the future of ALK+ care. ▶️ Watch now: youtube.com/watch?v=0DFJiw… #ALKpositive #ClinicalTrials

🫁Dirozalkib yielded promising efficacy among patients with ALK-positive NSCLC. Data from a phase 2 study presented at #AACR26 showed activity with the novel ALK inhibitor even among those with active brain metastases. #lcsm | @AACR

Personalized medicine is the future for ALK+ #LungCancer and data science is how we get there. Exciting work from our collaborators at @UTMDAnderson on digital twins using #AI to model patient-specific outcomes and guide treatment decisions pointing to a more precise, individualized approach to care. MS.BC02.01 |Ballroom 20 | 3.05pm

This Sunday, Mandy takes on the London Marathon — running for those who can’t. Every step is helping us fund research at the The Institute of Cancer Research to understand and overcome treatment resistance. Watch her story 🎥 + read more 👉 oncogeneresearch.org/icr-festival-t… #LCSM

How much do you know about clinical trials? From placebos to safety to eligibility, there are a lot of myths out there. Take our True or False Clinical Trials Quiz and see how you do! 🔬 alkpositive.org/blog/true-or-f… #LearnAboutALKPositive #ALKPositive #ClinicalTrials #ALKResearch

After discontinuing the NVL-655 trial due to liver toxicity, ALK-positive patient and ALK Positive board member, Jeff Sturm, accessed the investigational drug zidesamtinib through a single-patient IND. Read his experience here: alkpositive.org/blog/patient-p… #LearnAboutALKPositive

Join us at the 2026 @ASCO Annual Meeting in Chicago where we'll present clinical updates from our #ALK+ #NSCLC and #ROS1+ programs. Learn more: investors.nuvalent.com/2026-04-21-Nuv… #ASCO26

We’re excited to be here in Vienna this week for the @LungCancerEu 2026 Conference with the 46+ members and attendees 💙 Because advancing outcomes in lung cancer takes all of us — sharing, learning, and working together across borders. #LCSM